Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Karyopharm Therapeut (NQ: KPTI )

13.75 USD -0.07 (-0.51%)
Official Closing Price Updated: 7:59 PM EST, Mar 1, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,905,300
Open 14.11
Bid (Size) 13.84 (5)
Ask (Size) 13.90 (2)
Prev. Close 13.82
Today's Range 13.60 - 14.13
52wk Range 13.60 - 29.61
Shares Outstanding 60,216,752
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of... 
From PR Newswire
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in... 
From PR Newswire

Performance

YTD
-18.74%
-18.74%
1 Month
-10.71%
-10.71%
3 Month
-19.07%
-19.07%
6 Month
-9.60%
-9.60%
1 Year
-50.40%
-50.40%

More News

Read More
Karyopharm Announces Upcoming Virtual Investor Conference Participation
From PR Newswire
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
From PR Newswire
Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
From PR Newswire
Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma
From PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From PR Newswire
How The Parts Add Up: VHT Targets $258
Tags ETFs
From ETF Channel
Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China
Tags Market News FDA Small Cap
From Benzinga
Recap: Karyopharm Therapeutics Q4 Earnings
Tags Market News Earnings KPTI
From Benzinga
Karyopharm Therapeutics Inc (KPTI) Q4 2020 Earnings Call Transcript
Tags Market News KPTI
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]